BCAX vs AZN

AstraZeneca PLC (AZN) offers the better valuation at 28.

3x trailing P/E (18. 0x forward), making it the more compelling value choice. Analysts rate Bicara Therapeutics Inc. Common Stock (BCAX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AstraZeneca PLC (AZN) delivered a total return of +87.

0%, compared to +1. 6% for Bicara Therapeutics Inc. Common Stock (BCAX). Over 10 years, the gap is even starker: AZN returned +290. 3% versus BCAX's +1. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AstraZeneca PLC (AZN) is the lower-risk stock at 0.

67β versus Bicara Therapeutics Inc. Common Stock's 1. 79β — meaning BCAX is approximately 167% more volatile than AZN relative to the S&P 500. On balance sheet safety, Bicara Therapeutics Inc. Common Stock (BCAX) carries a lower debt/equity ratio of 0% versus 61% for AstraZeneca PLC — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190.

7% year-over-year, compared to -25. 0% for Bicara Therapeutics Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AstraZeneca PLC (AZN) is the more profitable company, earning 17.

5% net margin versus 0. 0% for Bicara Therapeutics Inc. Common Stock — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZN leads at 23. 4% versus 0. 0% for BCAX. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AZN: 14.

1% to $211. 00.

In this comparison, AZN (1.

8% yield) pays a dividend. BCAX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

67), 1. 8% yield, +290. 3% 10Y return). Bicara Therapeutics Inc. Common Stock (BCAX) carries a higher beta of 1. 79 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AZN: +290. 3%, BCAX: +1. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

AZN pays a dividend while BCAX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.